Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Apyx Medical holds annual shareholder meeting, votes on director slate

Apyx Medical holds annual shareholder meeting, votes on director slate

ReutersReuters2026/08/07 20:01
  • Apyx Medical held its annual shareholder meeting on Aug. 6, 2026.
  • Shareholders adopted the 2026 Share Incentive Plan, authorizing the plan’s framework without indicating any awards have been granted.
  • RSM US LLP was ratified as independent registered public accounting firm for the year ending Dec. 31, 2026.
  • An advisory resolution on named executive officer pay was approved.
  • Five directors were chosen to serve until the 2027 annual meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apyx Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036557), on August 07, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

JPMorgan warns: The EU 'Transition Fund' label is too strict and may hinder financing for emerging markets

JPMorgan's asset management division stated that the planned “transition” fund label in Europe could unnecessarily exclude related assets from an important source of financing.

智通财经2026/09/07 11:06
JPMorgan warns: The EU 'Transition Fund' label is too strict and may hinder financing for emerging markets